Literature DB >> 1390326

Antihypertensive efficacy and effects of nitrendipine on cardiac and renal hemodynamics in mild to moderate hypertensive patients: randomized controlled trial versus hydrochlorothiazide.

R Scaglione1, A Indovina, G Parrinello, R Lipari, L G Mulè, A Ganguzza, G Capuana, C G Stampino, G Licata.   

Abstract

In this study antihypertensive efficacy, safety, and the effects of short-term nitrendipine administration on central and renal hemodynamics were evaluated in mild to moderate hypertensives. Our final goal was to ascertain whether the reduction in blood pressure induced by nitrendipine treatment was associated with maintained renal function. After a run-in period with placebo, 26 hypertensives without cardiac or renal disease were randomly assigned to a double-blind 8-week controlled trial with nitrendipine (N) 20 mg once a day (13 pts) or hydrochlorothiazide (HCT) 25 mg once a day (13 pts). Renal hemodynamic measurements included effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) by radionuclide study using I-131 hippuran and Tc-99m, according to the methods described by Schlegel and Gates, respectively. Effective renal blood flow [ERBF = ERPF/(1-Ht)], filtration fraction (FF = GFR/ERPF), and renal vascular resistance (RVR = MBP x 80/ERBF) were also calculated. Other hemodynamic measurements included cardiac index (CI), left ventricular (LV) ejection fraction (EF), and total peripheral resistance (TPR) measured by the first-pass radionuclide angiography technique. At the end of N or HCT administration significant decreases (p less than 0.001) in SBP, DBP, and MBP vs. baseline values were observed in both hypertensive groups. In the N group a significant decrease (p less than 0.01) in TPR and RVR, and significant increases (p less than 0.05) in CI, ERPF, and ERBF were observed. In the HCT group a significant decrease (p less than 0.05) in RVR was found without significant changes in other hemodynamic parameters. No important side effects were observed with either therapy. In conclusion, nitrendipine was effective in reducting blood pressure in mild to moderate hypertensive patients and exerted favorable effects on cardiac and renal function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390326     DOI: 10.1007/bf00054562

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  25 in total

1.  Hemodynamic effects of nitrendipine on systolic ventricular function, diastolic ventricular function, and peripheral circulation in essential hypertension.

Authors:  E Kuschnir; R Castro; M Bendersky; H Sgammini; L Guzman; H Sgarlatta; M Castro
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

2.  Effects of nitrendipine on blood pressure, renin-angiotensin system, and kidney function in essential hypertension.

Authors:  N Glorioso; P Manunta; C Troffa; A Pazzola; A Soro; F Pala; M G Melis; P Madeddu; G Tonolo
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

3.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

Authors:  R B Devereux; D R Alonso; E M Lutas; G J Gottlieb; E Campo; I Sachs; N Reichek
Journal:  Am J Cardiol       Date:  1986-02-15       Impact factor: 2.778

Review 4.  Renal effects of beta blockade in essential hypertension.

Authors:  P W de Leeuw; W H Birkenhäger
Journal:  Eur Heart J       Date:  1983-07       Impact factor: 29.983

5.  Rapid method for the measurement of differential renal function: validation.

Authors:  A Chachati; A Meyers; J P Godon; P Rigo
Journal:  J Nucl Med       Date:  1987-05       Impact factor: 10.057

6.  Nitrendipine and other calcium entry blockers (calcium antagonists) in hypertension.

Authors:  S Kazda; B Garthoff; A Knorr
Journal:  Fed Proc       Date:  1983-02

7.  Glomerular injury in uninephrectomized spontaneously hypertensive rats. A consequence of glomerular capillary hypertension.

Authors:  L D Dworkin; H D Feiner
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

8.  Heterogeneity of systemic hemodynamic response to a new calcium entry blocker, nitrendipine.

Authors:  F M Fouad; M Aboul-Khair; R C Tarazi
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

9.  Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.

Authors:  S Anderson; T W Meyer; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

10.  Double-blind controlled study of rilmenidine versus hydrochlorothiazide in mild hypertension: clinical and renal haemodynamic evaluation.

Authors:  G Licata; R Scaglione; C Guillet; G Capuana; G Parrinello; A Indovina; R Lipari; G Mazzola; G Merlino
Journal:  J Hum Hypertens       Date:  1993-04       Impact factor: 3.012

View more
  4 in total

1.  One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study.

Authors:  Gaspare Parrinello; Salvatore Paterna; Daniele Torres; Pietro Di Pasquale; Manuela Mezzero; Gabriella La Rocca; Mauro Cardillo; Caterina Trapanese; Mario Caradonna; Giuseppe Licata
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

2.  Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients. A randomized controlled study versus placebo.

Authors:  G Licata; R Scaglione; A Ganguzza; G Parrinello; R Costa; G Merlino; S Corrao; P Amato
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.

Authors:  M Asif A Siddiqui; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure.

Authors:  Holly Digne-Malcolm; Matthew C Frise; Keith L Dorrington
Journal:  Front Physiol       Date:  2016-07-29       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.